London-based IAG, which also owns Aer Lingus and Iberia, said pretax profit in the third quarter of 2025 fell 2.1% on-year to EUR1.87 billion from EUR1.91 billion. Revenue was flat at EUR9.33 billion.

(Alliance News) - The FTSE 100 ended a losing week on a sour note, knocked by further heavy selling of US technology names and double-digit losses for blue chips Rightmove and IAG. The FTSE 100 index ...

(Alliance News) - Critical Metals PLC on Friday reported zero revenue and narrowed pretax loss in its full-year results as it reaffirmed target of operating the Molulu mine. The Democratic Republic of ...

The legal team urged the South African Supreme Court of Appeal to overturn a December 2023 ruling dismissing efforts to sue the British-based company over pollution in Kabwe, 150 kilometres north of ...

(Alliance News) - MedPal AI PLC on Friday announced the launch of its artificial intelligence-driven retail pharmacy website, initially targeting the weight-loss market.

Cap-XX reported that its earnings before interest, tax, depreciation and amortisation loss narrowed by 41% to AUD3.0 million from AUD5.1 million.

(Alliance News) - Trellus Health PLC on Friday said it signed a contract with "one of the largest global clinical research organisations". The London-based healthcare company said the 12-month ...

(Alliance News) - Bluefield Solar Income Fund Ltd on Friday warned that proposed UK government changes to renewable energy indexation could reduce its net asset value by up to 10%, as it urged ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday.

KKR also announced that Andrew Williams will become chair and Pat Murphy vice chair of Project Aurora Topco Ltd, the parent company that will oversee Spectris after completion of the takeover. Neither ...

The FTSE 100 index traded down 78.58 points, 0.8%, at 9,657.20. The FTSE 250 was down 109.06 points, 0.5%, at 21,795.97, and the AIM All-Share was down 3.03 points, 0.4%, at 750.10. The Cboe UK 100 ...

Evommune's IPO raised USD150 million through the offering of 9.4 million shares at USD16 per share. RTW Biotech said this valuation was a 22% step-up from the Evommune's prior holding value, and ...